ResMed Analyst Price Targets

ResMed Inc

RMDNYSE

$229.44

6.452.89%

In chiusura: Sep 15, 5:00 PM EST

$229.44

N/A

Post-mercato: 5:58 PM EST

PRO

Perché si muove?:ResMed shares are trading higher after RBC Capital upgraded the stock from ...

Wall Street analyst price targets and consensus rating for ResMed (RMD).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

6Buy

7Hold

1Sell

Consensus RatingNeutral# Analysts14Avg. Consensus PT$246Upside to Avg. PT+7.0%

Rating Trend — Last 9 Months

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	RBC Capital	Craig Wong-Pan	Upgrade	Sector Perform→Outperform	$244→$262
Aug 31, 2026	Keybanc	Brett Fishbin	PT Raise	Overweight	$255→$267
Aug 19, 2026	Rothschild & Co	Jackson Philips	Initiate	Neutral	$230
Aug 7, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Sector Perform	$234→$244
Aug 7, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$233→$225
Aug 7, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$260→$255
Aug 7, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$225→$215
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$235→$220
Jul 13, 2026	Citigroup	Laura Sutcliffe	Downgrade	Buy→Neutral	$270→$235
Jul 10, 2026	Jefferies	Matthew Taylor	PT Cut	Hold	$240→$225
Jul 8, 2026	RBC Capital	Craig Wong-Pan	PT Cut	Outperform	$321→$276
Jul 8, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$227→$225
Jun 22, 2026	Keybanc	Justin Patterson	PT Cut	Overweight	$290→$266
Jun 17, 2026	Morgan Stanley	David Bailey	Downgrade	Overweight→Equal-Weight	$286→$230
Jun 15, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$340→$270
May 1, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Outperform	$314→$321
May 1, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$270→$227
Apr 27, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$302→$290
Apr 15, 2026	JP Morgan	David Low	Reinstates	Overweight	—
Apr 9, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$345→$340